Bacteria and other microorganisms that have developed resistance to most antibiotics are largely known in the world as superbugs, but they can be a vague concept that the majority of people don’t care about. The UN doesn’t share the same opinion, however, as the international organization has just elevated the threat to a Crisis Level health issue. This is only the fourth time that the body of nations decided to do this, which is indicative of how seriously countries should take superbugs.
Modern antibiotics have been around for over 70 years, but the concept of using substances to combat bacterial infections have been around for far longer, Futurism reports. However, due to the long exposure to the drugs as well as the mass dumping of antibiotics in sewers, garbage sites, and even the ocean, resistant strains have started appearing.
These drug-resistant superbugs are not just a threat to humans either since there are also similarly toughened microorganisms that can infect crops, animals, and even farmed fish. As a result, Ban Ki-moon, the secretary general at the UN declared superbugs as “fundamental, long-term threat to human health, sustainable food production and development.”
In a recent gathering of UN officials, the secretary general detailed how superbugs currently threaten humanity as a whole. He also stressed that this is not a threat that’s far off into the future. It is happening right now.
“More than 200,000 newborn children are estimated to die each year from infections that do not respond to available antibiotics. An epidemic of multidrug-resistant typhoid is now sweeping across parts of Africa, being spread through water. Resistance to HIV/AIDS drugs is on the rise. Extensively drug-resistant tuberculosis has been identified in 105 countries. And resistance to antimalarial medicines is an urgent public health concern in the Greater Mekong sub-region,” Mr. Ban Ki-moon said.


Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 



